WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial

Written by

September 30, 2025 3:39 am EDT

Results showed the benefits of early initiation of WINREVAIR within the first year after PAH diagnosis

Continue Reading